GLP-1 agonists like Ozempic lower cancer risks in study

A study in JAMA suggests GLP-1 agonists, including Ozempic, reduce the risk of certain obesity-related cancers. Patients with Type 2 diabetes on these drugs had significantly lower risks of 10 out of 13 cancers studied. GLP-1 agonists like Ozempic may break the link between obesity and cancer. This could lead to more doctors prescribing these drugs over insulin for diabetes treatment.